1. Home
  2. DHY vs EMBC Comparison

DHY vs EMBC Comparison

Compare DHY & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DHY

Credit Suisse High Yield Bond Fund

HOLD

Current Price

$1.79

Market Cap

240.4M

Sector

Finance

ML Signal

HOLD

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$3.35

Market Cap

207.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHY
EMBC
Founded
N/A
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.4M
207.1M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
DHY
EMBC
Price
$1.79
$3.35
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.50
AVG Volume (30 Days)
669.3K
2.4M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
6.88%
EPS Growth
N/A
20.90
EPS
N/A
0.67
Revenue
N/A
N/A
Revenue This Year
N/A
$1.17
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.01
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$2.77
52 Week High
$2.16
$15.55

Technical Indicators

Market Signals
Indicator
DHY
EMBC
Relative Strength Index (RSI) 65.23 44.91
Support Level $1.75 $3.01
Resistance Level $2.05 $3.48
Average True Range (ATR) 0.02 0.18
MACD 0.01 0.13
Stochastic Oscillator 100.00 76.53

Price Performance

Historical Comparison
DHY
EMBC

About DHY Credit Suisse High Yield Bond Fund

Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: